Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer

Niels Reinmuth(Asklepios Fachkliniken München-Gauting), M Semik(Stadtarchiv Ibbenbüren)

European Respiratory Journal

November 1, 2000

10.1183/09031936.00.16599100

Cited by 54

Related Papers

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

|The Lancet Oncology|2019|1.7k

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

|Journal of Clinical Oncology|2021|818

IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

|Annals of Oncology|2018|58